PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer

Phung, Cao Dai; Le, Thien Giap; Nguyen, Van Hai; Vu, Thi Trang; Nguyen, Huong Thi; Kim, Jong Oh; Yong, Chul Soon; Nguyen, Chien Ngoc

doi:10.1007/s11095-020-02819-7

Cited by 25 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of anti-tumor and inhibition of inflammation effects of DHA, in recent years, more and more studies have focused on how to improve the efficacy of DHA. The main strategies to enhance the efficacy of DHA include modifying the chemical structure of DHA (55), developing new DHA derivatives (134), building multimeric DHA conjugates (135), and coupling other drugs with DHA to achieve targeted tumor therapy (37,59,(136)(137)(138). Liu et al construct the R 8 modified epirubicindihydroartemisinin liposomes for the treatment of NSCLC, and find R 8 modified epirubicin-dihydroartemisinin liposomes have a stronger killing effect on A549 cells.…”

Section: Summary and Future Outlookmentioning

confidence: 99%

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases

Jin

Fujimoto

2021

Front. Oncol.

View full text Add to dashboard Cite

Dihydroartemisinin (DHA) has been globally recognized for its efficacy and safety in the clinical treatment of malaria for decades. Recently, it has been found that DHA inhibits malignant tumor growth and regulates immune system function in addition to anti-malaria. In parasites and tumors, DHA causes severe oxidative stress by inducing excessive reactive oxygen species production. DHA also kills tumor cells by inducing programmed cell death, blocking cell cycle and enhancing anti-tumor immunity. In addition, DHA inhibits inflammation by reducing the inflammatory cells infiltration and suppressing the production of pro-inflammatory cytokines. Further, genomics, proteomics, metabolomics and network pharmacology of DHA therapy provide the basis for elucidating the pharmacological effects of DHA. This review provides a summary of the recent research progress of DHA in anti-tumor, inhibition of inflammatory diseases and the relevant pharmacological mechanisms. With further research of DHA, it is likely that DHA will become an alternative therapy in the clinical treatment of malignant tumors and inflammatory diseases.

show abstract

Section: Summary and Future Outlookmentioning

confidence: 99%

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases

Jin

Fujimoto

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…After nanoformulation administration, the same efficacy was demonstrated in in vivo studies, whereas an increase in antitumor effect was observed in tumor-bearing mice models (Jin et al, 2013;Chen et al, 2015;Zhang et al, 2015;Wang et al, 2016a;Wang et al, 2016b;Liu et al, 2016;Wang et al, 2018;Dong et al, 2019;Wang et al, 2019;Li et al, 2020;Phung et al, 2020). Antitumor effect was measured by using the tumor volume and tumor growth inhibition rate.…”

Section: Nanoformulationmentioning

confidence: 64%

“…Several in vitro and in vivo studies have been conducted to investigate the use of nanoparticles, nanocarriers, and liposomes as carriers for ARS, ART, and DHA to improve their delivery to the cancer cells. These new formulations improved solubility, exposure, and stability, increased cellular uptake, and enhanced permeability and retention in breast, colorectal, liver, lung, and cervical cancer cells (Chen J. et al, 2014;Chen et al, 2015;Tran et al, 2015;Leto et al, 2016;Liu et al, 2016;Tran et al, 2016;Tran et al, 2017;Wang et al, 2018;Wang et al, 2019;Phung et al, 2020). Both in vitro and in vivo studies revealed promising results with low IC 50 values (Zhang et al, 2015;Leto et al, 2016) and high rates of tumor inhibition (Jin et al, 2013;Chen et al, 2015;Wang et al, 2016b;Liu et al, 2016;Dong et al, 2019;Wang et al, 2019;Li et al, 2020).…”

Section: Nanoformulationmentioning

confidence: 99%

“…In the future research, combination therapy and nanotechnology should be further explored. The combinations of DHA with oxaliplatin (Duan et al, 2019), DHA with sorafenib (Wang et al, 2019), DHA with docetaxel (Li et al, 2020), and DHA with paclitaxel (Phung et al, 2020) along with the use of nanoparticles have been studied, and in vitro and in vivo data are promising, implying their viability for human trials.…”

Section: Nanoformulationmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Woon

Liu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer has become a global health problem, accounting for one out of six deaths. Despite the recent advances in cancer therapy, there is still an ever-growing need for readily accessible new therapies. The process of drug discovery and development is arduous and takes many years, and while it is ongoing, the time for the current lead compounds to reach clinical trial phase is very long. Drug repurposing has recently gained significant attention as it expedites the process of discovering new entities for anticancer therapy. One such potential candidate is the antimalarial drug, artemisinin that has shown anticancer activities in vitro and in vivo. In this review, major molecular and cellular mechanisms underlying the anticancer effect of artemisinin and its derivatives are summarised. Furthermore, major mechanisms of action and some key signaling pathways of this group of compounds have been reviewed to explore potential targets that contribute to the proliferation and metastasis of tumor cells. Despite its established profile in malaria treatment, pharmacokinetic properties, anticancer potency, and current formulations that hinder the clinical translation of artemisinin as an anticancer agent, have been discussed. Finally, potential solutions or new strategies are identified to overcome the bottlenecks in repurposing artemisinin-type compounds as anticancer drugs.

show abstract

“…Considering the role of M2 macrophages in the progression of CRC, an increasing interest has been exerted by the scientific community in regulating their influence on the tumorigenicity of colon cancer cells [1]. In the present in vitro study, we investigated the effects of Cuban brown propolis and its main component Nem on a widely used colon cancer cell line (HT-29 cells [32,33]). Besides Nem, which is the major constituent of the floral resin from Clusia rosea Jacq.…”

Section: Discussionmentioning

confidence: 99%

Cuban Brown Propolis Interferes in the Crosstalk between Colorectal Cancer Cells and M2 Macrophages

et al. 2020

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs), primarily the M2 phenotype, are involved in the progression and metastasis of colorectal cancer (CRC). Cuban brown propolis (Cp) and its main component Nemorosone (Nem) displays an antiproliferative effect on different cancer cells, including CRC cell lines. However, whether Cp and Nem could exploit its effect on CRC cells by targeting their relationship with TAMs remains to be elucidated. In this study, we differentiated the human monocytic THP-1 cells to M2 macrophages and confirmed this transition by immunofluorescence (IF) staining, qRT-PCR and zymography. An MTT assay was performed to determine the effect of Cp and Nem on the viability of CRC HT-29 cells co-cultured with M2 macrophages. Furthermore, the migration and invasion abilities of HT-29 cells were determined by Transwell assays and the expression levels of epithelial–mesenchymal transition (EMT) markers were analyzed by IF staining. We demonstrated that Cp and Nem reduced the viability of M2 macrophages and, accordingly, the activity of the MMP-9 metalloprotein. Moreover, we demonstrated that M2 macrophages produce soluble factors that positively regulate HT-29 cell growth, migration and invasion. These M2-mediated effects were counteracted by Cp and Nem treatments, which also played a role in regulating the expression of the EMT markers E-cadherin and vimentin. Taken together, our results indicate that Nem contained in Cp interferes in the crosstalk between CRC cells and TAMs, by targeting M2 macrophages.

show abstract

PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer

Cited by 25 publications

References 36 publications

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases

Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Cuban Brown Propolis Interferes in the Crosstalk between Colorectal Cancer Cells and M2 Macrophages

Contact Info

Product

Resources

About